Compare Stocks: REGN, SNAP, and BHC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BHC Bausch Health Cos	$6.34 -2.4%	$6.18	$4.33 ▼ $8.00	$2.37B	0.37	2.46 million shs	704,941 shs
REGN Regeneron Pharmaceuticals	$807.76 -1.4%	$791.83	$575.93 ▼ $859.34	$83.11B	0.16	815,094 shs	252,297 shs
SNAP Snap	$6.35 -0.1%	$5.67	$3.81 ▼ $9.13	$10.73B	1.07	45.39 million shs	10.84 million shs

The 7 Best High-Yield Dividend Stocks for 2027

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BHC Bausch Health Cos	+0.46%	+2.69%	+11.71%	+46.55%	+3.93%
REGN Regeneron Pharmaceuticals	+1.67%	+2.86%	+1.89%	+24.86%	+40.08%
SNAP Snap	-0.13%	-1.68%	+12.84%	+45.85%	-18.61%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BHC Bausch Health Cos	$6.34 -2.4%	$6.18	$4.33 ▼ $8.00	$2.37B	0.37	2.46 million shs	704,941 shs
REGN Regeneron Pharmaceuticals	$807.76 -1.4%	$791.83	$575.93 ▼ $859.34	$83.11B	0.16	815,094 shs	252,297 shs
SNAP Snap	$6.35 -0.1%	$5.67	$3.81 ▼ $9.13	$10.73B	1.07	45.39 million shs	10.84 million shs

The 7 Best High-Yield Dividend Stocks for 2027

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BHC Bausch Health Cos	+0.46%	+2.69%	+11.71%	+46.55%	+3.93%
REGN Regeneron Pharmaceuticals	+1.67%	+2.86%	+1.89%	+24.86%	+40.08%
SNAP Snap	-0.13%	-1.68%	+12.84%	+45.85%	-18.61%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BHC Bausch Health Cos	2.14	Hold	$8.00	26.28% Upside
REGN Regeneron Pharmaceuticals	2.77	Moderate Buy	$846.28	4.77% Upside
SNAP Snap	2.28	Hold	$7.68	21.08% Upside

Current Analyst Ratings Breakdown

Latest REGN, SNAP, and BHC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/21/2026	REGN Regeneron Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$960.00 ➝ $980.00
10/19/2026	REGN Regeneron Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$854.00 ➝ $865.00
10/15/2026	SNAP Snap	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
10/15/2026	REGN Regeneron Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Neutral ➝ Buy	$660.00 ➝ $978.00
10/14/2026	SNAP Snap	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Neutral	$5.70 ➝ $7.00
10/14/2026	SNAP Snap	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/8/2026	BHC Bausch Health Cos	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sector Perform	$9.00
10/8/2026	REGN Regeneron Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Sector Perform	$737.00 ➝ $810.00
10/7/2026	REGN Regeneron Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$772.00 ➝ $780.00
10/7/2026	REGN Regeneron Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Equal Weight	$758.00 ➝ $779.00
10/6/2026	REGN Regeneron Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$900.00 ➝ $950.00

(Data available from 10/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BHC Bausch Health Cos	$10.27B	0.23	$7.12 per share	0.89	$1.02 per share	6.21
REGN Regeneron Pharmaceuticals	$14.34B	5.80	$42.09 per share	19.19	$295.66 per share	2.73
SNAP Snap	$5.93B	1.81	N/A	N/A	$1.33 per share	4.77

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BHC Bausch Health Cos	$157M	-$2.96	N/A	1.58	N/A	-10.12%	-561.95%	6.31%	10/28/2026 (Estimated)
REGN Regeneron Pharmaceuticals	$4.50B	$40.46	19.95	15.26	1.37	27.86%	13.47%	10.34%	10/30/2026 (Estimated)
SNAP Snap	-$460.49M	-$0.18	N/A	79.31	N/A	-4.90%	-14.61%	-4.12%	11/4/2026 (Estimated)

Latest REGN, SNAP, and BHC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/4/2026	Q3 2026	SNAP Snap	$0.0047	N/A	N/A	N/A	$1.73 billion	N/A
10/30/2026	Q3 2026	REGN Regeneron Pharmaceuticals	$16.20	N/A	N/A	N/A	$4.56 billion	N/A
10/28/2026	Q3 2026	BHC Bausch Health Cos	$1.25	N/A	N/A	N/A	$2.72 billion	N/A
8/3/2026	Q2 2026	SNAP Snap	-$0.1218	-$0.10	+$0.0218	-$0.10	$1.54 billion	$1.60 billion
7/30/2026	Q2 2026	REGN Regeneron Pharmaceuticals	$10.16	$14.29	+$4.13	$12.23	$3.82 billion	$4.29 billion
7/29/2026	Q2 2026	BHC Bausch Health Cos	$0.96	$1.26	+$0.30	$0.68	$2.59 billion	$2.83 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BHC Bausch Health Cos	N/A	N/A	N/A	N/A	N/A
REGN Regeneron Pharmaceuticals	$3.76	0.47%	N/A	9.29%	N/A
SNAP Snap	N/A	N/A	N/A	N/A	N/A

Latest REGN, SNAP, and BHC Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/30/2026	REGN Regeneron Pharmaceuticals	quarterly	$0.94	0.46%	8/18/2026	8/18/2026	8/31/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BHC Bausch Health Cos	N/A	1.44	1.08
REGN Regeneron Pharmaceuticals	0.06	3.34	2.78
SNAP Snap	1.75	2.94	2.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BHC Bausch Health Cos	78.65%
REGN Regeneron Pharmaceuticals	83.31%
SNAP Snap	47.52%

Insider Ownership

Company	Insider Ownership
BHC Bausch Health Cos	20.67%
REGN Regeneron Pharmaceuticals	6.97%
SNAP Snap	22.68%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BHC Bausch Health Cos	20,300	374.38 million	297.00 million	Optionable
REGN Regeneron Pharmaceuticals	15,410	102.96 million	95.78 million	Optionable
SNAP Snap	5,261	1.69 billion	1.31 billion	Optionable

REGN, SNAP, and BHC Headlines

Recent News About These Companies

AppLovin vs. Snap: Which Technology Stock Is a Better Buy in 2026?

October 21 at 8:13 AM | fool.com

Snap Inc. $SNAP Stock Sold by Vontobel Holding Ltd.

October 20 at 4:55 AM | marketbeat.com

Snap Inc. $SNAP Stock Position Lifted by Assenagon Asset Management S.A.

October 17, 2026 | marketbeat.com

Snap (SNAP) Sees a More Significant Dip Than Broader Market: Some Facts to Know

October 16, 2026 | zacks.com

Snap Inc. $SNAP Stock Acquired by Curated Wealth Partners LLC

October 15, 2026 | marketbeat.com

Here's Why Snap (SNAP) Fell More Than Broader Market

October 14, 2026 | zacks.com

Social Media Stocks Rally as Truist Sets $1,000 Street-High Meta Target on Muse Adoption: Meta and Snap Climb 4%, Reddit Ticks Up

October 13, 2026 | 247wallst.com

Snap Inc. (NYSE:SNAP) Stock Has Consensus Target Price of $7.65

October 13, 2026 | americanbankingnews.com

Snap Inc. (SNAP) - What Are Analysts Saying About This Stock?

October 13, 2026 | marketbeat.com

Meta Climbs 4% on Muse Retention Data; Snap Rises 3%, Reddit Falls 3%

October 12, 2026 | 247wallst.com

Snap (SNAP) Faces Push To Raise $1 Billion Through Specs Stake Deal

October 9, 2026 | finance.yahoo.com

Investors Buy High Volume of Call Options on Snap (NYSE:SNAP)

October 9, 2026 | marketbeat.com

Snap (NYSE:SNAP) Stock Price Up 6% - Here's Why

October 9, 2026 | marketbeat.com

Snap Inc. Announces Date of Third Quarter 2026 Results Conference Call

October 8, 2026 | businesswire.com

Snap investor pushes company to sell stake in eyewear business

October 6, 2026 | latimes.com

Blue Duck Capital Urges Snap Inc. Board of Directors to Raise External Capital for Specs to Unlock Sum-of-the-Parts Value

October 6, 2026 | finance.yahoo.com

Blue Duck Capital Urges Snap Inc. Board of Directors to Raise External Capital for Specs to Unlock Sum-of-the-Parts Value

October 6, 2026 | prnewswire.com

Snap: You Don't Need An Advertising Recovery To Make Money

October 3, 2026 | seekingalpha.com

Snap Is Down 32% in 2026: Overlooked Bargain or Toxic Stock?

October 1, 2026 | 247wallst.com

Snap (NYSE:SNAP) Stock Price Up 5.9% - What's Next?

September 30, 2026 | marketbeat.com

Snap Jumps 6% as Fundamentals Outweigh Regulatory Pressure; Reddit Gains 4%, Meta Platforms Dips

September 30, 2026 | 247wallst.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

REGN, SNAP, and BHC Company Descriptions

Bausch Health Cos NYSE:BHC

$6.34 -0.16 (-2.39%)

As of 01:31 PM Eastern

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Regeneron Pharmaceuticals NASDAQ:REGN

$807.76 -11.33 (-1.38%)

As of 01:31 PM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Snap NYSE:SNAP

$6.34 -0.01 (-0.08%)

As of 01:31 PM Eastern

Snap Inc. operates as a technology company in North America, Europe, and internationally. The company offers Snapchat, a visual messaging application with various tabs, such as camera, visual messaging, snap map, stories, and spotlight that enable people to communicate visually through short videos and images. It also provides Spectacles, an eyewear product that connects with Snapchat and captures photos and video from a human perspective; and advertising products, including AR ads and Snap ads comprises a single image or video ads, collection ads, dynamic ads, story ads, and commercials. The company was formerly known as Snapchat, Inc. and changed its name to Snap Inc. in September 2016. Snap Inc. was founded in 2010 and is headquartered in Santa Monica, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest REGN, SNAP, and BHC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest REGN, SNAP, and BHC Earnings

Compare Dividends

Latest REGN, SNAP, and BHC Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

REGN, SNAP, and BHC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

REGN, SNAP, and BHC Company Descriptions

Bausch Health Cos NYSE:BHC

Regeneron Pharmaceuticals NASDAQ:REGN

Snap NYSE:SNAP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest REGN, SNAP, and BHC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest REGN, SNAP, and BHC Earnings

Compare Dividends

Latest REGN, SNAP, and BHC Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

REGN, SNAP, and BHC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

REGN, SNAP, and BHC Company Descriptions

Bausch Health Cos NYSE:BHC

Regeneron Pharmaceuticals NASDAQ:REGN

Snap NYSE:SNAP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools